Trial Profile
Real World Study of Patients Diagnosed with Relapsing-Remitting Multiple Sclerosis and initiated on Subcutaneous Interferon beta-1a or Dimethyl Fumarate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 11 May 2018 New trial record